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Summary 
Four melanoma proteins, MART-l, gpl00, tyrosinase, and tyrosinase-related protein-1  (gp75) 
were evaluated for recognition by HLA-A2-restricted  melanoma-specific  cytotoxic T lymphocytes 
(CTLs) derived from the tumor-infiltrating lymphocytes (TIL) of 10 different patients.  9 of 10 
TIL recognized MART-l, 4 recognized gpl00 (including 3 that also recognized MART-l), but 
none of the TIL recognized tyrosinase or gp75. Based on the known HLA-A2.1 peptide binding 
motifs, 23 peptides from MART-1 were synthesized  in an attempt to identify the epitopes recognized 
by TIL. Three peptides were recognized by TIL when pulsed on T2 target cells. One of the 
9-met peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis. This 
peptide was recognized by 9 of 10 HLA-A2-restricted melanoma-specific CTLs. Therefore, this 
peptide appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma- 
specific TIL and may be useful for the development  of immunotherapeutic strategies. 
T 
he adoptive transfer of cultured tumor-infiltrating lym- 
phocytes (TIL) with IL-2 can mediate tumor regression 
in mice with lung or liver metastases (1) and in 30-40% of 
patients with metastatic melanoma (2, 3). Many TIL recog- 
nize, in vitro, autologous melanoma cells. Allogeneic mela- 
noma cells and cultured melanocytes that share appropriate 
antigen-presenting HLA molecules are also recognized (4-7) 
suggesting that some CTLs recognize common antigens ex- 
pressed on melanoma and melanocytes (8, 9). Identification 
of these common antigens recognized by TIL can lead to in- 
creased understanding of the immune responses to tumors 
as well as to improvement of immunotherapeutic strategies 
for patients  with melanoma. 
The existence of multiple human melanoma antigens rec- 
ognized by T cells has been suggested (10, 11) and five an- 
tigens have previously been identified and isolated. MZ2-E 
encoded by the MAGE-1 gene and MZ2-D encoded by the 
MAGE-3 gene are expressed in melanoma, other types of 
cancers including head and neck cancer, lung cancer, colorectal 
cancer, breast cancer, sarcoma, and normal testis, and were 
recognized by HLA-Al-restricted CTL (12-14). MART-l, 
gpl00, and tyrosinase are specifically expressed in melanoma 
and melanocytes and are recognized by HLA-A2-restricted 
CTL (15-18). The epitopes of MART-1 recognized by T cells 
have not previously been identified. 
The importance of these antigens  in the recognition of 
melanoma by T  cells, in vivo, in patients  with melanoma 
has not yet been defined. The immunogenicity of these an- 
tigens in vivo may be related to the level of antigen expres- 
sion on the tumor surface  and the repertoire of T cell receptors 
expressed on patient's  T cells as well as the degree of toler- 
ance towards  these epitopes. 
In this  study,  we have identified  highly immunogenic 
common epitopes of MART-1 that were recognized by the 
majority of HLA-A2-restricted melanoma-specific TIL iso- 
lated from HLA-A2 melanoma patients. These common an- 
tigenic peptides may be useful for the development of im- 
munotherapeutic strategies against melanoma and in studies 
of the mechanism of T cell recognition and immunological 
tolerance to tumor antigens. 
Materials and Methods 
Generation of  Melanoma-specific CTL Lines and a Clone  from TIL. 
Melanoma-specific  CTL lines were  generated  by culturing a single 
cell suspension  made from metastatic  melanoma  with 6000 U/ml 
of IL-2 (Cetus-Oncology  Division, Chiton Corp., EmeryviUe,  CA) 
as previously  reported (19). A T cell clone, A42, was established 
by limiting dilution methods from patient 501. 
Assessment of Antigen Recognition by CTLs.  SlCr  release cyto- 
toxicity assays and cytokine  release  assays using ELISA to measure 
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tivity of TIL as previously described (17, 19). Melanoma cell lines 
were established in our laboratory. For analysis of the recognition 
of known antigens by TIL, the COS7 cell line transfected with 
cDNAs encoding either, MART-l, gpl00, tyrosinase, or tyrosinase- 
related protein (gp75) along with HLA-A2.1 cDNA were incubated 
with TIL for 20 h and the amount of IFN-7 secreted into the 
supernatant  was measured by ELISA (17). The cDNA encoding 
MART-1 or gpl00 in plasmid pcDNA3 (Invitrogen,  San Diego, 
CA) was previously cloned from a 501reel melanoma cDNA li- 
brary by screening with TILl235 or TILl200, respectively  (15, 17). 
The cDNA encoding tyrosinase in pcDNA3 was cloned from an 
888mel melanoma cDNA library by screening with TIL888 (20). 
The cDNA encoding tyrosinase related protein (gp75) in pCEV27 
plasmid was isolated from 501md melanoma cDNA library using 
a probe  generated  by PCR based on the reported  sequence of 
gp75 (21). 
Peptide Synthesis and Identification of  Antigenic Peptides.  Peptides 
were synthesized by a solid phase method using a multiple peptide 
synthesizer (model AMS 422; Gilson Co. Inc., Worthington, OH). 
The peptides were purified by HPLC on a C-4 column (VYDAC, 
Hesperia, CA) with 0.05% TFA/water-acetonitrile.  To identify 
the antigenic peptides, TIL lysis of T2 cell lines preincubated for 
2 h with each peptide was measured using a 51Cr release cytotox- 
icity assay. 
Results 
HLA-A2-restricted  Melanoma-specific TIL.  HLA-A2-re- 
stricted melanoma-specific CTL lines and a clone, A42, were 
established from lymphocytes infiltrating into tumors of 10 
melanoma patients. These TIL represented all available cell 
lines with HLA-A2-restricted antimelanoma reactivity grown 
in our laboratory and thus should be representative of other 
TIL with similar in vitro reactivity. These TIL recognized 
autologous and most allogeneic fresh or cultured melanoma 
cells expressing HLA-A2, but did not recognize HLA-A2- 
melanomas or HLA-A2 + nonmelanoma cell lines (5). They 
also recognized HLA-A2 + normal cultured melanocytes de- 
rived from neonatal skin (9, 15, 17). Thus, these TIL recog- 
nized nonmutated self-peptides derived from proteins expressed 
in melanoma and melanocytes in association with HLA-A2. 
Recognition of the Previously Identified Melanoma Proteins by 
TIL.  To evaluate the frequency of recognition of four pre- 
viously isolated  melanoma  proteins  including  MART-l, 
gpl00, tyrosinase, and tyrosinase-related protein (gp75), we 
tested the reactivity of TIL to COS7 cell lines transfected 
with cDNAs encoding these four proteins with or without 
the cDNA encoding HLA-A2.1. One of several experiments 
with nine TIL is shown in Table 1. Eight of the nine HLA- 
A2-restricted melanoma-specific TIL secreted IFN-  7  when 
incubated with COS7 cotransfected with MART-1 and HLA- 
A2.1. Only TILl200, which is a relatively oligoclonal CTL 
line (22), did not respond to this COS transfectant. Four TIL 
(620,  660,  1143, 1200) recognized gpl00 when transfected 
along with HLA-A2.1. TILl200 secreted large amounts of 
IFN-7 compared with TIL620, 660, and 1143, suggesting 
Table  1.  Recognition of Melanoma Antigens by HLA-A2-restricted Melanoma-specific TIL 
IFN-7 Secretion 
Stimulator  Transfected  TIL  TIL  TIL  TIL  TIL  TIL  TIL  TIL  TIL 
cell line  cDNA  HLA-A2  501  620  660  1074  1088  1128  1143  1200  1235 
pg/ml 
501mel  none  +  93  720  530  670  491  272  354  736  750 
397mel  none  -  0  0  0  0  0  0  0  0  0 
COS7  none  -  0  0  0  0  0  0  14  0  0 
COS7  HLA-A2.1  +  0  0  0  0  0  0  0  0  0 
COS7  MART-1  -  0  0  0  0  0  0  12  0  0 
COS7  gpl00  -  0  0  0  0  0  0  14  0  0 
COS7  tyrosinase  -  0  0  0  0  0  0  0  0  0 
COS7  gp75  -  0  0  0  0  0  0  0  0  0 
COS7  HLA-A2.1  +  MART-1  +  270  196  131  625  328  52  184  0  743 
COS7  HLA-A2.1  +  gpl00  +  0  89  17  0  0  0  41  391  8 
COS7  HLA-A2.1  +  tyrosinase  +  0  0  0  0  0  0  0  3  0 
COS7  HLA-A2.1  +  gp75  +  0  0  0  11  0  0  7  0  0 
IFN-7 was measured  in the supernatants after HLA-A2-restricted  melanoma-specific  TIL were coincubated  with COS7 cells cotransfected  with cDNAs 
encoding proteins expressed  in melanoma with or without HLA-A2.1 cDNA. All TIL except TILl200 secreted IFN-  7 when cultured with COS7 
cotransfected  with cDNAs encoding  MART-1 and HLA-A2.1. TIL620,  660, 1143, and 1200 secreted  IFN-7 when cultured with COS7 cotransfected 
with the cDNAs encoding gpl00 and HLA-A2.1. 
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lines  recognized  gpl00.  None  of  these  TIL  recognized 
tyrosinase  or  gp75  using  this  assay.  Thus,  MART-1  is  a 
common melanoma antigen recognized by most HLA-A2-re- 
stricted  TIL derived  from melanoma patients. 
Identification of MART-1 Epitopes  for TIL.  To identify the 
MART-1 epitopes for these TIL, 23 peptides were selected 
based on the known  peptide binding  motifs to HLA-A2.1 
(23-25), synthesized (>90% purity), and screened by testing 
lysis of the  HLA-A2.1 +  T2 cell line by TIL after incuba- 
tion of the T2 line with each peptide (Table 2). The T2 cell 
line was lysed well by all four HLA-A2-restricted melanoma- 
specific TIL tested when preincubated with either peptides 
M9-2, M10-3, or M10-4. Both 10-amino acid peptides, M10-3 
and M10-4, contain the M9-2 sequence, with M10-3 having 
an additional  glutamic acid at its NH2 terminus and M10-4 
having an extra isoleucine at its COOH-terminus. These pep- 
tides  are located in a  hydrophobic putative transmembrane 
domain in MART-1 (17). The same lysis was observed when 
other  HLA-A2 §  cells incubated  with  these peptides  were 
used as targets including the K4B and 501EBVB Epstein-Barr 
virus-transformed B cells or HMY-C1R B cells transfected 
with  the  HLA-A2.1  gene  (data not  shown). 
The peptides, M9-1, M9-2, M9-3, M10-2, M10-3, M10-4, 
and  M10-5  were  further  purified  and  titrated  in  order  to 
evaluate their relative ability to sensitize T2 cells to lysis by 
Table  2.  Lysis of T2 Cells Preincubated with Synthetic MART-1 Peptides 
Percent  specific lysis 
TIL  TIL  TIL 
Target  Peptide  A42  1235  660  1074 
501mel  none  47  30  31  41 
397mel  none  1  0  1  2 
T2  none  -  2  -  3  -  1  1 
T2  M9-1  TTAEEAAG  I  -10  -5  -5  -4 
T2  M9-2  AAG I G I LTV  64  80  40  56 
T2  M9-3  G I G I LTV I L  18  20  0  10 
T2  M9-4  G I LTV I LGV  1  -  1  -  3  2 
T2  M9-5  I LTV I LGVL  -  2  -  1  -  5  -  1 
T2  M9-6  LTV I LGVLL  1  0  1  0 
T2  M9-7  TVI  LGVLLL  -2  -3  -2  1 
T2  M9-8  Vl  LGVLLLI  1  5  -2  -2 
T2  M9-9  ALMDKSLHV  -1  -4  -8  0 
T2  M9-10  SLHVGTQCA  -1  1  -8  4 
T2  M9-11  PVVPNAPPA  -2  0  4  -  1 
T2  M9-12  NAPPAYEKL  1  -  2  0  6 
T2  M10-1  YTTAEEAAG  I  -4  -  2  -  3  3 
T2  M10-2  TAEEAAGIG I  7  11  12  15 
T2  M10-3  EAAG IG I LTV  55  66  31  51 
T2  M10-4  AAG I G I LTV I  34  68  29  21 
T2  M10-5  GILTVILGVL  -1  2  7  10 
T2  M10-6  I LTVI LGVLL  1  6  6  7 
T2  M10-7  LTVILGVLLL  -2  -1  -1  2 
T2  M10-8  TVILGVLLLI  -6  -1  -1  11 
T2  M10-9  RALMDKSLHV  3  5  8  11 
T2  M10-10  SLHVGTQCAL  -2  -8  2  9 
T2  M10-11  SLQEKNCEPV  3  2  2  9 
23 peptides (twelve 9-mers and eleven 10-mers) (>90% purity) were synthesized and the lysability by TIL clone A42, TIL lines TILl235, TIL660, 
and TILl074 derived from different patients was tested against HLA-A2 + T2 cells preincubated with each peptide (10 #g/ml) in a 4-h 51Cr release 
cytotoxicity  assay at E/T ratio of 20:1 for A42 and 40:1 for other TIL lines. T2 cells were lysed well when incubated with M9-2, M10-3, and 
M10-4. M10-3 and M10-4 contain the entire M9-2 sequence (underlined). 
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Figure  1.  Titration of MART-1 peptides  for recognition by TIE T2 
cells were incubated  with varied concentrations  of the purified MART-1 
peptides, M9-1, M9-2, M9-3, M10-2, M10-3, M10-4, and M10-5, and lysis 
by TIL clone A42 or TIL line TILl235 was measured by 4-h stCr release 
cytotoxicity assay at an E/T ratio of 20:1 for A42 and 40:1 for TILl235. 
Peptide M9-2 sensitized T2 cells at a concentration of 1 ng/ml. The purified 
peptide M10-4 was recognized by TILl235, but not by A42. (M9-1 ]---], 
M9-2  O---O,  M9-3  m---I,  M10-2  A---A,  M10-3  V---V,  M10-4 
I---I,  ~1o-5  +---+). 
MART-1 reactive TILl235 or T cell clone A42 (Fig. 1). The 
purified peptides M9-2, M10-3, and M10-4 were required in 
minimum concentrations of 1 ng/ml, 100 ng/ml, and 1,000 
ng/ml, respectively.  The purified M10-4 was not recognized 
by TIL clone A42 even at 10/~g/ml as shown in Fig. 1. M9-1, 
M9-3, M10-2, and M10-5 peptides were not recognized by 
either A42 or TILl235. 
Recognition of MART-I Peptides by HLA-A2-restricted  TIL 
Established  from Different Patients.  To evaluate whether a variety 
of HLA-A2-restricted MART-l-specific TIL recognized the 
same or different epitopes in the MART-1 antigen, lysis of T2 
cells preincubated with each peptide was tested with TIL 
derived from 10 melanoma patients. A representative experi- 
ment with  10 TIL is shown in Table 3.  M9-2 and M10-3 
were recognized by 9 of 10 TIL (only TILl200 were nega- 
tive) as well as the A42 clone with the same pattern of lysis 
as COS7 cells cotransfected with cDNAs encoding MART-1 
and HLA-A2.1.  Only TIL620 and TILl088 demonstrated 
low level of nonspecific lysis of T2 cells without peptides 
or  after  the  addition  of irrelevant  peptides,  but  showed 
significant increase of lysis of T2 cells preincubated with M9-2, 
M10-3, and M10-4 peptides. The recognition of M10-4 differed 
Table  3.  Recognition of MART-I  Peptides by HLA-A2-restricted Melanoma-specific TIL 
Percent  specific lysis 
TIL  TIL  TIL  TIL  TIL  TIL  TIL  TIL  TIL  TIL  clone 
Target  Peptide  501  620  660  1074  1088  1128  1143  1200  1235  1363  A42 
~g/ml 
501mel  none  42  49  35  32  31  19  24  41  32  43  41 
397mel  none  3  16  6  1  1  4  3  3  3  4  1 
T2  none  0  7  -3  -6  7  -6  -7  -6  -7  -7  -6 
T2  M9-1  (1)  4  15  -  4  1  31  1  -  5  -  1  1  4  3 
T2  M9-2  (1)  86  75  73  79  98  30  36  2  92  82  91 
T2  M9-2  (0.001)  52  49  23  32  81  9  6  1  10  41  63 
T2  M9-3  (1)  5  25  0  1  19  0  1  -  2  0  -  2  -  4 
T2  M10-2  (1)  10  22  5  8  21  8  3  7  7  7  6 
T2  M10-3  (1)  84  68  68  73  79  24  27  1  42  67  62 
T2  M10-3  (0.001)  91  50  33  25  86  13  14  0  14  39  1 
T2  M10-4  (1)  83  47  16  35  80  6  3  1  14  53  0 
T2  M10-4  (0.001)  0  11  3  0  14  4  -1  -1  2  -3  -3 
T2  M10-5  (1)  4  14  1  4  13  2  3  0  3  0  2 
Lysability by TIL clone A42 and TIL lines derived from 10 patients  of T2 cells preincubated  with the purified peptides M9-1,  M9-2, M9-3,  M10-2, 
M10-3,  M10-4, and M10-5  was tested  in a 4-h slCr release assay at an E/T ratio of 20:1 for A42 and 40:1  for other TIL lines.  9 of 10 TIL lysed 
T2 cells incubated  with peptides  M9-2 or M10-3.  7 of 10 TIL lysed T2 incubated  with peptide M10-4  at a concentration  of 1 /zg/ml. 
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to M10-4 by the T cell clone A42 or the T cell line TILl235 
(Fig. 1). Higher concentrations (1/~g/ml) of M10-4 were re- 
quired for lysis than were required for M9-2 or M10-3. These 
10 TIL and clone A42 also secreted cytokines including IFN-'y, 
GM-CSF, and TNF-t~ when incubated with T2 cells prein- 
cubated with M9-2 or M10-3 (data not shown). Therefore, 
M9-2 or M10-3 are common epitopes recognized by a majority 
of HLA-A2-restricted melanoma-specific TIL. 
Discussion 
In this study, we have analyzed the relative frequency of 
recognition of known melanoma proteins by T ceils derived 
from the TIL of 10 melanoma patients. We have also identified 
the common epitopes, M9-2 and M10-3,  in the MAtLT-1 
antigen that were dominantly recognized by nine of these 
TIL. The cDNA encoding MAILT-1 was previously isolated 
by cDNA expression cloning using TILl235  in screening 
assays. MART-1 is a ll8-amino acid protein containing a single 
transmembrane domain and is expressed in most melanoma 
cells as well as cultured melanocytes and retina (17) similar 
to the expression pattern of gpl00 (15) and tyrosinase, gpl00 
is recognized by 4 of 10 TIL, but recognition of tyrosinase 
or tyrosinase related protein was not detected by any of the 
10 TIL in these assays. 
Based on dose response analysis, peptide M9-2 most effec- 
tively sensitized T2 cells for lysis (Fig.  1), suggesting that 
this peptide may be naturally processed and presented on tumor 
cells. The T cells recognizing M9-2 may react with peptide 
M10-3 or M10-4 because the latter 10-met peptides contain 
the 9-amino acid sequence of peptide M9-2. There is some 
difference in recognition of these three peptides by different 
TIL. For example, M10-4 was poorly recognized by the T 
cell clone A42, but was well recognized by some TIL lines, 
although a higher concentration of M10-4 was necessary to 
observe the lysis. This may be due to the variation of TCR 
affinity for the M9-2 and M10-4 peptides in the context of 
HLA-A2,  or alternatively, TIL lines may contain different 
T cell clones that only recognize either M9-2 or M10-4. Pep- 
tides M10-3 and M10-4 may also be naturally processed and 
presented by tumor cells.  The existence of multiple mela- 
noma antigens presented by HLA-A2 has previously been 
suggested by analyzing the recognition of  melanoma cell clones 
by a variety of T cell clones (10, 11) or by analyzing HPLC 
peptide fractions that were isolated from HLA-A2 melanoma 
cells (26,  27).  The M9-2, M10-3, and M10-4 peptides ana- 
lyzed in this paper may correspond to peptides present in 
HPLC fractions found by others to stimulate T cells. If these 
peptides are present on tumor cells, it should be possible to 
identify them in extracts from melanoma cells. 
The observation that most HLA-A2-restricted TIL from 
melanoma patients recognize common MART-1 peptides but 
not tyrosinase or gp75  suggests that  the M9-2 or M10-3 
MART-1 peptides may be more immunogenic in inducing 
T  cell responses in vivo than other known melanoma an- 
tigens. However, it is not clear whether these proteins are 
tumor rejection antigens. Some of the TIL used in this study 
were injected along with IL-2 into autologous patients, and 
interestingly, all four TIL (620, 660, 1143, 1200) that recog- 
nize gpl00 effectively induced tumor regression (>50% reduc- 
tion of tumor). All but TILl200 also recognized MART-1. 
Since many factors are likely to be involved in the induction 
of tumor regression by adoptive therapy with TIL, it is difficult 
at this time to conclude which of these melanoma antigens, 
if any, are responsible for rejection. It would be interesting 
to conduct clinical trials using active immunization with these 
identified  melanoma  antigens  or  with  CTL  populations 
specifically sensitized in vitro to individual antigenic epitopes 
such  as  the  MART-1  peptides  described in  this  report. 
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